Latest Manufacturing News

Racura Oncology reported a transformative quarter with key scientific discoveries, expanded clinical programs, and a robust cash position of $20.94 million, setting the stage for pivotal cancer trials in 2026.

CurveBeam AI reported steady progress in Q2 FY26 with five new device purchase orders, a $4 million milestone payment pending receipt, and key regulatory submissions underway in the US and China.

Arovella Therapeutics has secured a crucial regulatory nod from the U.S. FDA, allowing its lead CAR-iNKT cell therapy, ALA-101, to enter first-in-human clinical trials targeting blood cancers.

INOVIQ Limited has completed a $10.2 million capital raise to accelerate development of its exosome-based ovarian cancer screening test and CAR-exosome therapeutics, alongside key leadership appointments and promising preclinical results.

Fortuna Metals has confirmed significant high-grade rutile mineralisation at its newly acquired Mkanda project in Malawi, supported by a successful A$3.5 million capital raise to advance exploration.

Li-S Energy has made significant strides in Q4 2025, securing a major government grant, forging key defence partnerships, and commissioning Australia’s first lithium foil production line.

Nova Eye Medical has reported a record US$6.1 million in global sales for the December 2025 quarter, marking a 38% year-on-year increase and strong momentum across key markets. The company’s innovative iTrack™ technology continues to drive growth, supported by expanded manufacturing capacity and advancing clinical programs.

Sea Forest Limited has exceeded its breakeven target for its methane-reducing feed additive SeaFeed™, securing commitments for over 118,000 cattle and expanding commercial trials with major industry partners.

NOVONIX is ramping up industrial-grade synthetic graphite production with mass manufacturing slated for 2026, while battery-grade output for Panasonic faces delays until late 2027. The company also navigates a major offtake termination and secures significant funding to support its growth.

Cleo Diagnostics has broadened its U.S. market opportunity to around 2 million women annually and is on track to complete its pivotal clinical trial early this year, supported by a $5 million capital raise and regulatory progress.

MyEco Group Ltd has reported record quarterly sales of its MyEcoBag® products, alongside improved gross margins and a significant reduction in operating cash outflows following a strategic operational restructure.

Adisyn Ltd has achieved a critical milestone in its pioneering low-temperature graphene deposition technology, validated by an independent expert, positioning the company for potential semiconductor industry integration.